ArticleInternational journal of clinical oncology2026
Efficacy and safety of endoscopic resection followed by chemoradiotherapy with S-1 plus cisplatin for esophageal cancer.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChemoradiotherapy (CRT) with 5-fluorouracil plus cisplatin is commonly used as additional treatment after endoscopic resection (ER) for esophageal squamous cell carcinoma (ESCC); however, metastatic recurrence remains a concern. S-1 is an oral fluoropyrimidine that has shown efficacy in combination with cisplatin and radiotherapy. This single-center, single-arm, exploratory phase II study evaluated the efficacy and safety of ER followed by CRT using S-1 plus cisplatin for superficial ESCC (UMIN000014684).
methodsPatients with ESCC diagnosed with stage pT1a-MM or pT1b-SM disease or lymphovascular invasion after ER were enrolled. CRT consisted of two cycles of S-1 administered twice daily on days 1 to 14 and cisplatin (75 mg/m²) on day 1 every 4 weeks, in conjunction with radiotherapy (40.0-41.4 Gy). The primary endpoint was 3-year overall survival (OS). Progression-free survival and adverse events were also examined.
resultsThirty-eight patients underwent CRT with S-1 plus cisplatin. The 3-year OS and progression-free survival rates were 94.7% (90% confidence interval [CI], 84.1-98.3%) and 92.1% (90% CI, 80.8-96.9%), respectively. The lower limit of the 90% CI for 3-year OS exceeded the predefined threshold. Grade ≥ 3 adverse events occurred in 55% of patients, with no cases of febrile neutropenia. Metastatic recurrence was observed in two patients (5%).
conclusionsER followed by CRT with S-1 plus cisplatin showed favorable survival outcomes with a manageable toxicity profile in patients with superficial ESCC requiring additional treatment, although careful monitoring of adverse events and further validation is warranted.
Indexed as
Identifiers
42584816What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.